Navigation Links
Statement from the American Diabetes Association Related to ACCORD Trial Announcement
Date:2/6/2008

ACCORD data raises concerns; Group advises patients with diabetes to maintain good control of blood glucose and talk to their doctor

ALEXANDRIA, Va., Feb. 6 /PRNewswire-USNewswire/ -- In response to today's announcement by the National Heart, Lung, and Blood Institute, which sponsors the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Trial to stop the intensive blood glucose (sugar) control sub-study in ACCORD due to safety concerns, the American Diabetes Association strongly encourages people with diabetes not to alter their course of treatment without first consulting with their health care team. The American Diabetes Association continues to encourage good control of blood glucose for the management of diabetes and its complications.

The ACCORD trial randomized patients with diabetes and vascular disease or multiple cardiovascular risk factors to an intensive treatment program targeting normal blood glucose values and an A1C less than 6 percent or a standard treatment program with an A1C between 7 percent and 7.9 percent. The intensive participants in ACCORD are now being switched to the standard treatment program because of an increased death rate in the intensive treatment program (14 deaths per 1000 patients per year versus 11 per 1000 patients per year in the standard treatment program; a difference of 0.3 deaths per 100 patients per year).

The American Diabetes Association continues to advise people with diabetes to strive for an A1C (a measure of long-term blood glucose control) of less than 7 percent. Recent data indicates that more than half of the population with diabetes in the U.S. have an A1C less than 7 percent and this overall level of glucose control appears to be of great benefit rather than harm.

The importance of glucose control in diabetes is firmly established. Evidence from the landmark Diabetes Control and Complications Trial (DCCT), and the U.K. Prospective Diabetes Study (UKPDS) show t
'/>"/>

SOURCE American Diabetes Association
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Statement of Andrea Kavanagh, Director, Pure Salmon Campaign, on the Science Sea Lice Study
2. AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic
3. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
4. Statement From The National Conclave on HIV/AIDS Policy for Black Clergy
5. Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
6. More Than 1.5 Million Americans Sickened, Injured or Killed by Medication Errors Each Year; Seniors Most at Risk
7. Second Thoughts about Fluoride, Reports Scientific American
8. Olympic Gold Medalist Kristi Yamaguchi Joins American Lung Association of Michigan to Address Seriously Low Vaccination Rates; Urge Metro-Detroiters to Get Immunized This Season
9. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
10. News from the American Heart Association
11. Long-Term Safety and Efficacy Data on Promacta(TM) (Eltrombopag) Presented at American Society of Hematology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2012)... Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ), ... commercialization of products for central nervous system disorders, ... at the Society for Research on Biological Rhythms ... The first poster entitled Pleiomorphic Expression of ... insight into the challenges faced by individuals suffering ...
(Date:5/22/2012)... ALLEGAN, Mich., May 22, 2012  Perrigo Company ... final approval from the U.S. Food and Drug ... for butoconazole nitrate 2% vaginal cream, the generic ... submit a substantially complete ANDA with a paragraph ... marketing exclusivity. Perrigo is working exclusively with KV Pharmaceutical ...
(Date:5/22/2012)... Generics, a division of Prodigy Health Supplier Corporation ... generic equivalent of the branded drug Camptosar by ... Laboratories to develop a portfolio of oncology products. ... developed through the partnership that will add consistent ... market, which has experienced record levels of shortages ...
Breaking Medicine Technology:Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 2Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 3Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 2Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 3GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 1GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 2GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 3GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 4ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 1ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 2MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 1MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 2MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 3MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 4
... Planning for Phase 3 Trial Initiation on Track ... Limited (ASX: PGL; Nasdaq: PGLA) today announced it ... Contract Research,Organisation, to utilise their services for a ... the execution of the,Phase 3 clinical trial of ...
... Topic of Drug Repurposing and ... Indian Clinical Trial Strategy, ... biopharmaceutical company, announced today,that Chief Executive Officer, John Maki, and ... 234th American Chemical,Society National Meeting on Sunday, August 19, 2007. ...
Other Medicine Technology:Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88 2Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88 3Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA 2Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA 3
(Date:5/23/2012)... Reporter , , TUESDAY, May 22 (HealthDay News) -- ... procedure, which involves threading a camera through the ... But a new study has found that patients ... less time-consuming CT-based colon scan. Colonoscopy ... colon cancer screening. Computed tomography (CT) colonography -- ...
(Date:5/23/2012)... The number of viral infections during infancy is not ... new study from researchers in the Netherlands. While viral ... childhood, this association was due in part to decreased ... particularly rhinovirus, are thought to be a risk factor ... this association is due to the viruses themselves or ...
(Date:5/23/2012)... A tiny, resilient metal wire designed to gather ... patients with severe heterogeneous emphysema, a subtype of the ... lungs, according to the results of a multicenter international ... wire, called a lung volume reduction coil (LVRC), can ... place of more invasive procedures used to improve the ...
(Date:5/23/2012)... present findings on prostate cancer risk, screening, treatment ... of the American Urological Association May 19-23 in ... to provide expert comment for reporters covering the ... presented and their embargo dates include: , ... surgery hormone therapy , Embargoed until 10:30 a.m. ...
(Date:5/22/2012)... OR Bend Research Inc., a leading ... the expansion of its existing hot-melt extrusion ... 18mm Leistritz twin-screw mixer/extruder. , The ... existing 27mm Leistritz and 19mm Baker Perkins ... continuous high-shear wet-granulation capabilities. Many projects have ...
Breaking Medicine News(10 mins):Health News:Patients Prefer More Invasive Form of Colon Scan: Study 2Health News:Patients Prefer More Invasive Form of Colon Scan: Study 3Health News:Viral infections in infancy are not associated with wheezing symptoms in later childhood 2Health News:Tiny implanted coil improves lung function in patients with severe emphysema 2Health News:Tiny implanted coil improves lung function in patients with severe emphysema 3Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 2Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 3Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 4
... A well-informed consumer will be a healthy one, too ... prescription filled is such a routine task, most people ... potentially a big mistake, according to medical experts -- ... cases, do real harm. , Pharmacists and health-care advocates ...
... to the Marketing Messages for Advair,and Xolair, According ... WALTHAM, Mass., Nov. 5 Decision Resources one ... on pharmaceutical and,healthcare issues, finds that physicians and ... asthma medicine to use.,Physicians indicate that brands conveying ...
... 9:00 a.m. EST -, VALENCIA, Calif., Nov. 5 ... results for the third quarter ended,September 30, 2008., ... were $69.1,million, compared to $75.6 million for the third ... in research and development,(R&D) expenses which totaled $55.6 million ...
... Stay Balanced Through the ... ... and New York Times best-selling author Ellie Krieger, of Food Network,fame, ... health. Yo-Plus contains live and active probiotic cultures,specifically designed for digestive ...
... CARY, N.C., Nov. 5 Cornerstone Therapeutics,Inc. ... focused on,developing and commercializing prescription medications for ... terms of the recently,completed merger between Cornerstone ... A. Collard, 42, president and chief executive,officer ...
... Inc. announced that,it reached a new high of more than ... case during the third quarter of 2008.,In addition, the quarter ... case activity with a leap of 64 %. Revenue and ... Through nine months of 2008,CardiacAssist has also set records in ...
Other Medicine News:Health News:When It Comes to Prescription Drugs, Get Smart 2Health News:When It Comes to Prescription Drugs, Get Smart 3Health News:Physicians Rank Schering-Plough's Marketing Messages for Asmanex as the Most Appealing in the Asthma Drug Market 2Health News:MannKind Corporation Reports Third Quarter Financial Results 2Health News:MannKind Corporation Reports Third Quarter Financial Results 3Health News:MannKind Corporation Reports Third Quarter Financial Results 4Health News:MannKind Corporation Reports Third Quarter Financial Results 5Health News:MannKind Corporation Reports Third Quarter Financial Results 6Health News:MannKind Corporation Reports Third Quarter Financial Results 7Health News:MannKind Corporation Reports Third Quarter Financial Results 8Health News:Healthy Eating Expert Ellie Krieger Joins Yoplait(R) Yo-Plus(TM) to Raise Awareness of Digestive Health 2Health News:Healthy Eating Expert Ellie Krieger Joins Yoplait(R) Yo-Plus(TM) to Raise Awareness of Digestive Health 3Health News:Cornerstone Therapeutics Announces New Board of Directors 2Health News:Cornerstone Therapeutics Announces New Board of Directors 3Health News:Cornerstone Therapeutics Announces New Board of Directors 4Health News:Cornerstone Therapeutics Announces New Board of Directors 5Health News:CardiacAssist, Inc. Announces Record Breaking Site Activity and Financial Results 2
... the revolutionary OxiMax® Pulse Oximetry System, ... Nellcor's best-in-class pulse oximetry with the ... OxiMax N-595 Pulse Oximeter is equipped ... technology, which enables it to withstand ...
The Model 340 is intended for continuous pulse oximetry and has visual and audible alarms to aid with patient monitoring....
A pocket-sized pulse oximeter. Perfect for the physician's office, emergency medicine, hospitals and clinics, and home health care....
... The Autocorr Pulse Oximeter with SAC ... unique patented software to extract SpO 2 ... in a new way. This cost-effective ... study functions as standard features, and a ...
Medicine Products: